Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
Associated filings
- 22 Nov 22 424B3 Prospectus supplement
- 30 Aug 22 EFFECT Notice of effectiveness
- 24 Aug 22 POS AM Prospectus update (post-effective amendment)
- 19 Jul 22 424B5 Prospectus supplement for primary offering
- 5 Apr 22 EFFECT Notice of effectiveness
- 31 Mar 22 POS AM Prospectus update (post-effective amendment)
- 19 Jan 22 EFFECT Notice of effectiveness
- 19 Jan 22 424B3 Prospectus supplement
-
7 Jan 22 F-1 Registration statement (foreign)
ADXN similar filings
- 11 May 23 Registration statement (foreign) (amended)
- 3 May 23 Registration statement (foreign)
- 19 Aug 22 Registration statement (foreign)
- 7 Jan 22 Registration statement (foreign)
- 6 Jan 21 Registration statement (foreign) (amended)
- 14 Dec 20 Registration statement (foreign)
- 23 Jan 20 Registration statement (foreign) (amended)
Filing view
External links
Exhibit 23.3
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in this Registration Statement on Form F-1 of Addex Therapeutics Ltd of our report dated April 24, 2020 relating to the financial statements, which appears in Addex Therapeutics Ltd's Annual Report on Form 20-F for the year ended December 31, 2020. We also consent to the reference to us under the heading “Experts” in such Registration Statement.
/s/ PricewaterhouseCoopers SA
Geneva, Switzerland
January 7, 2022